化疗引起的噁心呕吐治疗市场（按药物类别、给药途径、治疗类型、通路、最终用户、呕吐风险和患者年龄组划分）—全球预测，2025-2032年

预计到 2032 年，化疗引起的噁心和呕吐治疗市场将成长至 52.8 亿美元，复合年增长率为 6.74%。

关键市场统计数据
基准年 2024	31.3亿美元
预计年份：2025年	33.4亿美元
预测年份 2032	52.8亿美元
复合年增长率 (%)	6.74%

这是一份重点突出的高管入门指南，阐述了当代临床挑战、以患者为中心的治疗结果以及塑造止吐治疗路径的战略要务。

化疗引起的噁心和呕吐仍然是接受细胞毒性药物和标靶治疗的患者最主要的副作用之一。临床医生在选择止吐方案时，总是会考虑疗效、耐受性和患者的生活质量，而支付方和医疗服务提供者则会仔细权衡成本、可及性和依从性等因素。同时，药理学、辅助支持治疗和给药方式的进步正在重塑治疗选择和临床路径。

识别临床实务、药物研发、报销模式和病患参与的变革性变化，以重新定义止吐治疗服务。

化疗引起的噁心呕吐治疗领域正经历一系列变革，这些变革影响着临床实践、研发重点以及支付者的决策。在临床上，人们越来越重视预防而非仅仅关注症状的偶发性控制，这推动了多机制治疗方案的采用，并加强了指南指导下的治疗。这些变化反映了人们对催吐途径的更深入了解，以及对能够最大限度减少后续併发症和非计划医疗资源利用的治疗方案的日益青睐。

2025年美国关税调整的累积经济、政策和供应链影响及其对止吐疗法可及性的影响

关税调整等政策变化会对药品供应链、采购惯例以及最终的临床用药产生连锁反应。 2025年美国关税调整导致进口成本和行政流程复杂度发生变化，并波及製造商、合约经销商和机构采购商。这些影响不仅体现在直接采购环节，也体现在关键支持性治疗药物的策略采购决策和库存管理实务。

可操作的細項分析揭示了药物类别、给药途径、治疗方法、分销管道、最终用户、呕吐风险和年龄组如何影响临床选择。

细緻的细分观点揭示了影响临床和操作偏好的因素，这些因素涵盖药物类别、给药途径、治疗类型、分销管道、最终用户、噁心风险和患者年龄。在药物类别选择方面，受体标靶药物在中高风险止吐方案的预防策略中占据主导地位。在5-HT3受体拮抗剂中，GranisetronOndansetron、昂丹司琼、Palonosetron和雷莫司琼因其起效时间、持续时间和耐受性而受到关注，而地塞米松和Methylprednisolone等皮质类固醇仍作为基础辅助性治疗。多巴胺受体拮抗剂在抢救治疗和特定适应症中仍然有效，其中甲氧氯普胺和丙氯拉嗪保留了其独特的临床作用。 NK1受体拮抗剂，包括Aprepitant和福沙吡坦，是高风险通讯协定联合治疗的关键药物。

影响药品取得、处方趋势、监管演变和供应韧性的区域趋势：美洲、欧洲/中东/非洲和亚太地区

区域趋势对监管方式、药品取得途径和供应稳定性有显着影响。在美洲，医疗卫生系统高度重视实证预防和整合式诊疗路径，以促进患者遵循指引建议的治疗方案。完善的采购系统为合约签订和库存策略提供支持，从而稳定药品取得。在欧洲、中东和非洲地区，监管的多样性和报销模式的差异导致了不同的药品获取途径，一些地区优先考虑集中采购，而另一些地区则依赖区域性处方集决策，这影响了新药及其组合药物的上市速度。

竞争情报重点关注领先的止吐药物开发商的创新、伙伴关係、产品线定位和商业化策略

止吐药领域的企业竞争取决于渐进式创新、产品系列的广度、伙伴关係策略和商业执行力等因素的综合作用。如果差异化配方、缓释性特性或新型给药系统能够转化为医疗机构依从性或营运效率的显着提升，那么拥有这些特性的研发企业就能获得相对优势。同样重要的是，透过策略联盟可以扩大分销管道、共同开发联合治疗，或整合用于监测患者症状和依从性的互补型数位健康工具。

旨在改善临床疗效、增强供应韧性、优化定价和提升病患服务的实用策略建议

致力于提升治疗效果和营运韧性的领导者应制定优先行动计划，协调临床、商业和供应链目标。首先，应在临床环境中统一预防通讯协定，最大限度地减少治疗方法选择上的差异，并确保呕吐风险分层能够促进实践的一致性。统一临床路径可以减少不必要的实践差异，并支援可预测的采购和库存计划。

为确保研究结果的可靠性，我们采用了一套全面的调查方法：涵盖资料收集、资讯来源三角验证、分析架构、检验程序以及专家参与等各个面向。

本报告的分析整合了多项一手和二手研究资料，以确保研究结果的三角验证和检验。资料收集包括对同侪审查文献、监管文件和临床指南的系统性回顾，以及对临床医生、药房部门主管、供应链经理和行业高管的结构化访谈。这种混合方法能够同时捕捉定量模式和定性背景讯息，从而为决策提供依据。

策略要务、持续挑战和发展路径的关键整合，对于改善止吐治疗中的患者疗效和营运韧性至关重要。

这项综合分析突显了持续存在的挑战，包括：根据呕吐风险和患者状况匹配治疗方法方案、主动管理供应链韧性以及产生真实世界证据以促进广泛应用。持续存在的挑战还包括协调临床医生、支付方和采购机构相关利益者的奖励，以及确保在不同的地理环境中公平地获得治疗。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 开发长效神经激肽-1受体拮抗剂以改善化疗引起的噁心和呕吐（CINV）的治疗
• 整合数位健康监测工具，用于个人化预防化疗引起的噁心和呕吐 (CINV) 并支持用药依从性
• 针对多种化疗引起的噁心呕吐（CINV）路径并提高给药便利性的口服固定剂量复方製剂的出现，为患者带来了便利。
• 扩大大麻素类治疗方法难治化疗引起的噁心和呕吐的研究
• 药物基因体学分析在为化疗患者个体化製定止吐方案方面正受到越来越多的关注。
• 在致吐性极强的化疗通讯协定中，越来越多地采用指引推荐的四联止吐疗法
• 开发一种长效型经皮止吐贴剂，以提高门诊病患的依从性
• 评估奥Olanzapine辅助治疗预防化疗迟发性噁心呕吐的临床试验数量迅速增加
• 过渡到低成本的非专利止吐药製剂有助于促进市场竞争，并降低治疗成本。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章化疗引起的噁心和呕吐治疗药物市场

• 5-HT3受体拮抗剂
  • Granisetron
  • Ondansetron
  • Palonosetron
  • 拉莫塞特龙
• 皮质类固醇
  • 地塞米松
  • Methylprednisolone
• 多巴胺受体拮抗剂
  • 甲氧氯普胺
  • 丙氯拉嗪
• NK1受体拮抗剂
  • Aprepitant
  • 福沙普利坦

第九章化疗引起的噁心呕吐治疗市场（依给药途径划分）

• 静脉注射
• 口服

第十章化疗引起的噁心呕吐治疗市场（依治疗类型划分）

• 联合治疗
  • 双重疗法
    • 5-HT3受体拮抗剂和NK1受体拮抗剂
    • 5-HT3受体拮抗剂和类固醇
    • NK1受体拮抗剂和类固醇
  • 三联疗法
• 单药治疗

第十一章化疗引起的噁心呕吐治疗市场（按通路划分）

• 医院药房
• 网路药房
• 零售药房

第十二章化疗引起的噁心和呕吐治疗市场（按最终用户划分）

• 居家医疗环境
• 医院
• 专科诊所

第十三章化疗引起的噁心呕吐治疗市场（依呕吐风险划分）

• 高风险
• 低风险
• 轻度风险
• 中等风险

第十四章 依患者年龄层分類的化疗引起的噁心和呕吐治疗市场

• 成人
• 儿童

第十五章 各地区化疗引起的噁心呕吐治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章化疗引起的噁心呕吐治疗市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 各国化疗引起的噁心呕吐治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Helsinn Healthcare SA
  • GlaxoSmithKline plc
  • Heron Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Mylan NV
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

The Chemotherapy Induced Nausea & Vomiting Treatment Market is projected to grow by USD 5.28 billion at a CAGR of 6.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.13 billion
Estimated Year [2025]	USD 3.34 billion
Forecast Year [2032]	USD 5.28 billion
CAGR (%)	6.74%

A focused executive primer defining contemporary clinical challenges, patient-centric outcomes, and strategic imperatives shaping antiemetic therapy pathways

Chemotherapy induced nausea and vomiting remains one of the most consequential adverse effects experienced by patients undergoing cytotoxic or targeted oncology therapies. Clinicians continue to balance efficacy, tolerability, and patient quality of life when selecting antiemetic regimens, while payers and providers navigate cost, access, and adherence considerations. In parallel, advances in pharmacology, adjunctive supportive care, and administration modalities are reshaping therapeutic choices and clinical pathways.

The modern treatment landscape increasingly emphasizes individualized approaches that account for emetic risk, comorbidities, and patient-specific factors such as age and prior response to antiemetics. As a result, stakeholders across clinical practice, pharmacy operations, and commercial strategy require clear, evidence-informed perspectives on drug classes, regimen composition, and delivery settings. This introduction consolidates core themes that persistently influence therapeutic decision-making and frames the subsequent analysis in terms of clinical imperatives, stakeholder incentives, and operational constraints.

Moving forward, the report navigates the intersection of clinical innovation, regulatory developments, and supply chain dynamics. It highlights how incremental improvements in antiemetic efficacy, shifts in administration preference, and evolving care delivery models collectively affect patient experience and institutional readiness. The intent here is to set a pragmatic foundation that aligns clinician priorities with organizational objectives, enabling informed choices that protect patients' quality of life while maintaining operational viability.

Identifying transformative shifts across clinical practice, drug development, reimbursement models, and patient engagement that are redefining antiemetic care delivery

The treatment landscape for chemotherapy induced nausea and vomiting is undergoing a sequence of transformative shifts that touch clinical practice, development priorities, and payer decision-making. Clinically, a stronger emphasis on prevention ahead of breakthrough management has driven adoption of multi-mechanistic regimens and reinforced guideline-driven care. These shifts reflect improved understanding of emetic pathways and a growing preference for regimens that minimize downstream morbidity and unplanned care utilization.

From a development perspective, pharmaceutical strategies prioritize formulations and combinations that enhance adherence and enable outpatient administration. This trend is complemented by innovation in oral agents and extended half-life formulations that reduce dosing complexity. Simultaneously, regulatory emphasis on real-world effectiveness and patient-reported outcomes is shaping trial design and post-approval evidence generation, encouraging sponsors to embed pragmatic endpoints that resonate with clinicians and payers alike.

Payer and provider systems are converging on value-based criteria that stress both clinical outcomes and total cost of care. Consequently, stakeholders are reassessing formulary placement and contracting strategies to favor therapies that demonstrate consistent prophylactic benefit. At the same time, patient engagement initiatives and digital health tools are being deployed to improve adherence and symptom reporting, which helps clinicians titrate therapy more precisely and detect breakthrough nausea earlier.

Taken together, these shifts are not isolated; they are mutually reinforcing. Improved agents enable ambulatory care models, which in turn change distribution and procurement practices. As the landscape evolves, organizations that integrate clinical, commercial, and operational perspectives will be best positioned to convert scientific advances into sustained improvements in patient experience.

Cumulative economic, policy and supply chain ramifications of the 2025 United States tariff adjustments and effects on antiemetic treatment access

Policy changes such as tariff adjustments can have a cascade of effects across pharmaceutical supply chains, procurement practices, and ultimately clinical access. United States tariff changes implemented in 2025 introduced modifications to import costs and administrative complexity that ripple through manufacturers, contract distributors, and institutional buyers. These effects manifested not only in direct procurement operations but also in strategic sourcing decisions and inventory management practices for critical supportive care medicines.

In practical terms, procurement teams faced shorter planning horizons and increased emphasis on local sourcing where feasible, prompting some health systems to diversify supplier relationships. Manufacturers and contract distributors responded by reassessing production footprints, increasing engagement with domestic contract manufacturing organizations, and in some cases prioritizing higher-margin formulations. These operational responses aimed to mitigate exposure to tariff-related cost shifts and to maintain continuity of supply.

Clinicians and pharmacy leaders adapted by refining ordering cadence, reinforcing stock rotation policies, and expanding therapeutic substitution protocols to preserve continuity of care. At the same time, payers and procurement entities examined contractual terms and rebate structures to ensure predictable access to guideline-recommended regimens. Importantly, these adjustments were not uniformly disruptive; institutions with advanced supply chain analytics and close manufacturer partnerships were able to maintain steady access with minimal clinical impact.

Overall, the policy environment in 2025 underscored the importance of supply chain visibility, diversified sourcing strategies, and proactive engagement between manufacturers and health systems. These lessons have durability beyond immediate policy cycles and should inform long-term planning for essential supportive care therapies.

Actionable segmentation insights revealing how drug classes, administration routes, therapy regimens, distribution channels, end users, emetic risk and age cohorts drive clinical choice

A nuanced segmentation lens reveals the drivers of clinical choice and operational preference across drug class, route, therapy type, distribution, end user, emetic risk, and patient age. When considering drug class selection, receptor-targeted agents dominate prophylactic strategies for moderately and highly emetogenic regimens; within 5-HT3 receptor antagonists, practitioners weigh differences among granisetron, ondansetron, palonosetron and ramosetron based on onset, duration and tolerability, while corticosteroids such as dexamethasone and methylprednisolone continue to be foundational adjuncts. Dopamine receptor antagonists remain relevant for rescue and select indications, with metoclopramide and prochlorperazine retained for their clear clinical roles, and NK1 receptor antagonists, including aprepitant and fosaprepitant, are integral to combination regimens for high-risk protocols.

Route of administration is a critical operational consideration; the choice between intravenous and oral delivery shapes inpatient workflows, outpatient infusion center throughput, and home care feasibility. Intravenous administration offers immediate bioavailability and is often favored in acute settings, while oral options support ambulatory care and greater patient convenience. Treatment strategy is further refined through therapy type selection, where monotherapy may be appropriate for low risk scenarios but combination therapy-either dual or triple regimens-dominates prophylaxis for higher emetic risk. Dual regimens commonly combine 5-HT3 and NK1 agents, 5-HT3 agents with steroids, or NK1 agents with steroids, each pairing chosen to target complementary pathways and maximize prophylactic benefit.

Distribution channel considerations influence accessibility and adherence. Hospital pharmacies play a central role for inpatient and infusion center needs, retail pharmacies support community dispensing, and online pharmacies are increasingly used for repeat dosing and home delivery models. End user contexts-home care settings, hospitals, and specialty clinics-each impose distinct constraints and opportunities: home care demands simplified regimens and clear patient education materials, hospitals require integration with electronic prescribing and formulary controls, and specialty clinics prioritize regimen efficacy aligned with oncologic protocols.

Emetic risk stratification-classified as high, moderate, low or minimal-remains the primary clinical axis around which regimen intensity is determined, and patient age groups, whether adult or pediatric, require tailored dosing, formulation selection and tolerability considerations. Pediatric patients often need age-appropriate formulations and dosing strategies that reduce administration burden, whereas adult cohorts accommodate a broader range of oral and intravenous options. In sum, rigorous segmentation supports precise therapeutic alignment: selecting the appropriate agent and regimen for a patient's emetic risk and care setting while accounting for distribution and age-related considerations leads to better adherence and clinical outcomes.

Regional dynamics shaping access, prescribing trends, regulatory evolution, and supply resiliency across Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert substantial influence over regulatory approaches, access pathways, and supply resilience. In the Americas, health systems display a strong emphasis on evidenced-based prophylaxis and integrated care pathways that promote adherence to guideline-recommended regimens; procurement sophistication supports contracting arrangements and inventory strategies that stabilize access. Across Europe, Middle East & Africa, regulatory heterogeneity and variable reimbursement models create differentiated pathways to access, with some jurisdictions prioritizing centralized procurement and others relying on localized formulary decision-making, which impacts how quickly new formulations or combinations are adopted.

In Asia-Pacific, rapid expansion of oncology services and growing emphasis on ambulatory care are accelerating demand for oral and long-acting antiemetic options. Regional manufacturing footprints and supplier diversification in this area also influence product availability and pricing dynamics. Across all regions, localized clinical practice patterns, national guideline endorsements, and health system procurement capabilities drive how therapies are implemented in practice. For example, countries with robust outpatient oncology infrastructure are more likely to favor oral regimens that support home administration, whereas regions with constrained outpatient capacity may rely more heavily on infusion-based strategies.

Supply chain considerations differ by region as well; jurisdictions with established domestic production capacity exhibit greater resilience to import disruptions, while those reliant on international suppliers are more sensitive to policy shifts and logistical constraints. Clinicians and health system leaders must therefore calibrate procurement strategies, formulary decisions, and patient education efforts to local realities, leveraging regional partnerships and cross-border collaboration where possible to maintain continuity of care and equitable access.

Competitive intelligence highlighting innovation, partnerships, pipeline positioning and commercialization strategies of major antiemetic developers

Competitive dynamics among companies in the antiemetic space are defined by a combination of incremental innovation, portfolio breadth, partnership strategies, and commercialization execution. Developers with differentiated formulations, extended-release profiles, or novel delivery systems gain relative advantage when those attributes translate into measurable adherence improvements or workflow efficiencies for providers. Equally important are strategic alliances that broaden distribution reach, enable co-development of combination approaches, or integrate adjunctive digital health tools to monitor patient symptoms and adherence.

Generic manufacturers and specialty pharmaceutical companies play complementary roles: generics provide price-competitive access for established agents, while specialty firms focus on next-generation formulations, combination products, or indications that extend prophylactic coverage. Pipeline activity often centers on combination packaging, novel oral formulations that simplify dosing, and improvements in tolerability, reflecting an industry focus on reducing the clinical burden of nausea while enabling care in ambulatory and home settings.

Commercial strategy matters; companies that deploy targeted clinician education, real-world evidence generation, and value communications aligned with payer priorities achieve stronger formulary positioning. Moreover, manufacturing resilience and supply chain transparency are critical differentiators, as buyers increasingly demand predictable supply and collaborative contingency planning. Ultimately, firms that integrate clinical evidence, operational reliability, and clear value propositions are best positioned to influence treatment protocols and capture sustained clinical trust.

Practical strategic recommendations for leaders to improve clinical outcomes, shore up supply resilience, refine pricing and enhance patient services

Leaders seeking to strengthen therapeutic impact and operational resilience should pursue a set of prioritized actions that align clinical, commercial, and supply chain objectives. First, standardize prophylaxis protocols across care settings to minimize variability in regimen selection and ensure that emetic risk stratification drives consistent practice. Aligning clinical pathways reduces unwarranted practice variation and supports predictable procurement and inventory planning.

Second, diversify sourcing and build contractual mechanisms that ensure continuity of supply. Long-term supplier agreements, regional manufacturing partnerships, and flexible contracting terms help institutions respond to policy shifts and logistical disruptions. In parallel, enhance supply chain visibility through analytics that forecast consumption, monitor inventory levels in near real time, and alert stakeholders to potential constraints before they impact patient care.

Third, prioritize regimen simplification where clinically appropriate. Favoring formulations and combinations that reduce dosing complexity supports adherence in home care settings and decreases administration burden in outpatient infusion centers. Complement regimen optimization with robust patient education and digital adherence supports that improve symptom reporting and early intervention for breakthrough nausea.

Finally, invest in evidence generation that resonates with payers and clinicians. Real-world effectiveness studies, patient-reported outcome data, and comparative effectiveness analyses provide persuasive inputs for formulary discussions and guideline updates. By integrating these strategic initiatives-protocol standardization, supply diversification, regimen simplification, and targeted evidence generation-leaders can both elevate patient outcomes and reduce operational risk.

Comprehensive research methodology covering data collection, source triangulation, analysis frameworks, validation steps and expert engagement for robust insights

The analysis underpinning this report synthesizes multiple primary and secondary research streams to ensure triangulated and validated insights. Data collection combined systematic review of peer-reviewed literature, regulatory documentation, and clinical guidelines with structured interviews of clinicians, pharmacy leaders, supply chain managers, and industry executives. This mixed-methods approach enabled the capture of both quantitative patterns and qualitative context that inform decision-making.

Analytical frameworks included comparative regimen assessment, distribution channel mapping, and stakeholder impact analysis. These frameworks guided evaluation of drug classes, administration routes, and therapy types in relation to clinical outcomes and operational feasibility. Validation steps included cross-referencing interview findings with published guidelines and supply chain data, seeking convergence across independent sources to minimize bias and enhance reliability.

Expert engagement involved advisory consultations with clinicians and pharmacy directors to test assumptions and prioritize areas of operational risk. Where ambiguity emerged, targeted follow-up interviews and additional desk research were deployed to refine conclusions. Together, these methods produced a coherent evidence base that supports pragmatic recommendations and highlights where further bespoke research would add value.

Conclusive synthesis of strategic imperatives, enduring challenges and growth pathways to elevate patient outcomes and operational resilience in antiemetic care

The synthesis presented here underscores several enduring imperatives: therapies should be selected to match emetic risk and patient context; supply chain resilience must be actively managed; and evidence generation tailored to real-world practice is essential for broader adoption. Persistent challenges include aligning stakeholder incentives across clinicians, payers, and procurement entities, and ensuring equitable access across diverse regional contexts.

Opportunities are clear. Simplified regimens and patient-friendly formulations support the transition to ambulatory and home-based care models, while targeted evidence that emphasizes patient-reported outcomes can shift payer calculus toward broader coverage. Operationally, investments in predictive inventory analytics and supplier diversification reduce exposure to policy-driven disruptions and support continuous care delivery.

In closing, success will require coordinated action: clinical teams must standardize approaches based on risk stratification; procurement leaders must secure adaptable supply arrangements; and commercial teams must communicate value in terms that matter to clinicians and payers. By aligning these elements, organizations can achieve sustained improvement in patient experience and operational performance in the management of chemotherapy induced nausea and vomiting.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Development of long-acting neurokinin-1 receptor antagonists for improved CINV management
• 5.2. Integration of digital health monitoring tools for personalized CINV prophylaxis and adherence support
• 5.3. Emergence of oral fixed-dose combination antiemetics targeting multiple CINV pathways and improving dosing convenience
• 5.4. Expansion of research on cannabinoid-based therapies for refractory chemotherapy induced nausea and vomiting
• 5.5. Growing focus on pharmacogenomic profiling to tailor antiemetic regimens for individual chemotherapy patients
• 5.6. Increasing adoption of guideline recommended quadruple antiemetic regimens in high emetogenic chemotherapy protocols
• 5.7. Development of long-acting transdermal antiemetic patches to enhance patient compliance in outpatient settings
• 5.8. Surge in clinical trials evaluating adjunctive olanzapine for prevention of delayed chemotherapy induced nausea and vomiting
• 5.9. Shift towards low-cost generic antiemetic formulations driving market competition and therapy affordability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class

• 8.1. 5-HT3 Receptor Antagonists
  • 8.1.1. Granisetron
  • 8.1.2. Ondansetron
  • 8.1.3. Palonosetron
  • 8.1.4. Ramosetron
• 8.2. Corticosteroids
  • 8.2.1. Dexamethasone
  • 8.2.2. Methylprednisolone
• 8.3. Dopamine Receptor Antagonists
  • 8.3.1. Metoclopramide
  • 8.3.2. Prochlorperazine
• 8.4. NK1 Receptor Antagonists
  • 8.4.1. Aprepitant
  • 8.4.2. Fosaprepitant

9. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route Of Administration

• 9.1. Intravenous
• 9.2. Oral

10. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Therapy Type

• 10.1. Combination Therapy
  • 10.1.1. Dual Regimen
    • 10.1.1.1. 5-HT3 And NK1
    • 10.1.1.2. 5-HT3 And Steroid
    • 10.1.1.3. NK1 And Steroid
  • 10.1.2. Triple Regimen
• 10.2. Monotherapy

11. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User

• 12.1. Home Care Settings
• 12.2. Hospitals
• 12.3. Specialty Clinics

13. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Emetic Risk

• 13.1. High
• 13.2. Low
• 13.3. Minimal
• 13.4. Moderate

14. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Patient Age Group

• 14.1. Adult
• 14.2. Pediatric

15. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Merck & Co., Inc.
  • 18.3.2. Eisai Co., Ltd.
  • 18.3.3. Helsinn Healthcare SA
  • 18.3.4. GlaxoSmithKline plc
  • 18.3.5. Heron Therapeutics, Inc.
  • 18.3.6. Teva Pharmaceutical Industries Ltd.
  • 18.3.7. Sandoz International GmbH
  • 18.3.8. Mylan N.V.
  • 18.3.9. Dr. Reddy's Laboratories Ltd.
  • 18.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 247. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 248. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 249. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 250. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOS